ANTIDIABETIC ACTIVITY OF Curculigo latifolia EXTRACTS IN IN VITRO AND IN VIVO STUDIES

NUR AKMAL BINTI ISHAK

IB 2014 9
ANTIDIABETIC ACTIVITY OF Curculigo latifolia EXTRACTS IN IN VITRO AND IN VIVO STUDIES

By

NUR AKMAL BINTI ISHAk

Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in Fulfillment of the Requirements for the Degree of Doctor of Philosophy

January 2014
COPYRIGHT

All material contained within the thesis, including without limitation text, logos, icons, photographs and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia
Abstract of thesis presented to the Senate of Universiti Putra Malaysia in Fulfillment of the Requirements for the degree of Doctor of Philosophy

ANTIDIABETIC ACTIVITY OF Curculigo latifolia EXTRACTS IN IN VITRO AND IN VIVO STUDIES

By

NUR AKMAL BINTI ISHAK

January 2014

Chairman : Professor Maznah Ismail, PhD
Faculty : Institute of Bioscience

Curculigo latifolia (C. latifolia) plant grows wildly in tropical Asia especially in Malaysia. C. latifolia fruit has 9000 times the sweetness of sucrose. The sweet taste of C. latifolia fruit is due to a protein known as curculin. This indicates that C. latifolia plant has the potential to be used as an alternative low-calorie sweetener for diabetic patients. Besides, natural phenolic compounds contained in C. latifolia which posses antioxidant activity can also be used to prevent and treat diabetes. In the present study, antidiabetic properties of C. latifolia in cell lines (in vitro) and in diabetic-induced rats were determined.

Different parts of C. latifolia plant (fruit, root and leaf) were extracted using distilled water and then were freeze dried into powder. Total phenolic content and free radicals scavenging activity of C. latifolia fruit, root and leaf extracts were determined. C. latifolia fruit and root extracts exhibited higher scavenging free radicals activity (1.0 mg/ml) and followed by leaves extract (1.2 mg/ml). Besides, C. latifolia fruit extracts showed high phenolic content (95 mg GAE/100 g extract) and followed by roots (90 mg GAE/100 g extract), leaf in hot (100°C) water (83 mg GAE/100 g extract) and leaf in normal (at room temperature) water (74 mg GAE/100 g extract). In in vitro study, different concentrations (0.01, 0.025, 0.05, 0.1, 0.5, 1.0 and 3 mg/ml) of C. latifolia fruit, root and leaf extracts were screened for cytotoxicity effect towards BRIN- BD11 pancreatic, L6 myotubes and 3T3 adipocytes cells using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium) (MTS) assay. Results showed that C. latifolia fruit and root extracts did not cause toxicity towards BRIN-BD11 pancreatic, L6 myotubes and 3T3 adipocytes cells. However, C. latifolia leaf extracts at 2.3 mg/ml caused 50% BRIN BD11 cell death. Furthermore, the effect of C. latifolia as potential antidiabetic agent was evaluated by measuring: (1) insulin secretion by BRIN-BD11 pancreatic cells (2) radio labelled 2-Deoxy-D-glucose (2DOG) uptake by 3T3 adipocyte and L6 myotubes and (3) adiponectin secretion by 3T3 adipocytes. Results from insulin assay showed that C. latifolia roots extract increased 40% of insulin over basal secretion followed by C. latifolia fruits extract (35%) in BRIN BD11 pancreatic cells. Whereas, leaves extract did not show significant increment.
Meanwhile, results from 2DOG uptake activity showed that *C. latifolia* fruits extract significantly increased ($p<0.05$) 2DOG activity with insulin present up to 13 fold (at 0.05 mg/ml) in 3T3 adipocytes and 16 fold (at 0.1 mg/ml) in L6 myotubes. However, *C. latifolia* roots extract at 0.05 mg/ml significantly increased ($p<0.05$) 2DOG activity without insulin presence up to 2 fold in 3T3 adipocytes and L6 myotubes. Present study also indicates that with insulin presence, *C. latifolia* leaves extract at 0.1 mg/ml increased 21 fold of adiponectin secretion. However without insulin presence, *C. latifolia* roots extract increased 6 fold adiponectin secretion.

The effectiveness of *C. latifolia* fruit and root extracts in increasing insulin secretion, 2DOG uptake and adiponectin secretion *in vitro* study were then confirmed by study on diabetes-induced rats. Combination of *C. latifolia* fruit and root (1:1) v/v used to treat the diabetes-induced rats. Diabetes rats were developed by feeding high fat diet (HFD) which contained 56.9% calorie contributed by fat and low dose (40 mg/kg bw) STZ injection. After acclimation period, rats were fed high fat diet for 30 days and were then injected with 40 mg/kg bw of STZ via intravenous (iv) injection at the tail. Rats were divided into seven groups; 1) normal rats, 2) obese rats (only fed with HFD), 3) diabetic rats (induced with HFD and low dose STZ), 4) diabetic rats treated with 50 mg/kg b.w of *C. latifolia* fruit:root (1:1) extracts, 5) diabetic rats treated with 100 mg/kg b.w of *C. latifolia* fruit:root extracts, 6) diabetic rats treated with 200 mg/kg b.w of *C. latifolia* fruit:root extracts and 7) diabetic rats treated with 10 mg/kg b.w of glibenclamide. Treatment period was 30 days. Before and after treatments, biochemical parameters such as glucose, insulin, adiponectin, total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides (TG), urea, creatinine, alanine aminotransferase (ALT) and plasma $\gamma$-glutamyltransferase (GGT) were measured. Results showed that 200 mg/kg b.w of *C. latifolia* fruit:root extracts reduced significantly ($p<0.05$) 65% plasma glucose and 49% of total cholesterol level. Besides, with the same concentration it also increased 12% insulin and 41% of adiponectin levels in plasma. Furthermore, 50, 100 and 200 mg/kg b.w of *C. latifolia* fruit:root extracts showed that urea, creatinine, ALT and GGT levels in diabetic-induced rats were reduced towards normalcy after 30 days of treatment.

The regulatory effects of *C. latifolia* fruit:root extracts on genes involved in glucose and lipid metabolisms were further studied. Ten genes; IGF-1, IRS-1, GLUT4, PPAR$\gamma$, PPAR$\alpha$, AdipoR1, AdipoR2, leptin, lipoprotein lipase and lipase were analyzed using GenomeLab GeXP Genetic Analysis System. Results showed that treatment with 200 mg/kg b.w of *C. latifolia* fruit:root extracts effectively improved glucose metabolism in diabetic-induced rats due to increase expression of insulin signaling receptor (IRS-1 (4 fold) and IGF-1 (4 fold)), glucose transporter (GLUT 4 (2 fold)) and peroxisome proliferator-activated receptor (PPAR$\gamma$ (8 fold) and PPAR$\alpha$ (2 fold)). It also showed to improve lipid metabolism by increasing the expression of adiponectin receptor (AdipoR1 (5 fold) and AdipoR2 (4 fold)), leptin (5 fold), lipase (3 fold) and lipoprotein lipase (2 fold).

Based on the current findings, it can be concluded that *C. latifolia* fruit:root extracts exhibit antidiabetic properties due to higher total phenolic content and its ability to scavenge free radicals. It effectively improved glucose and lipid metabolisms in diabetic-induced rats by increased IGF-1, IRS-1, GLUT4, PPAR$\gamma$, PPAR$\alpha$,
AdipoR1, AdipoR2, leptin, lipoprotein lipase and lipase genes regulation. All of the results demonstrate potential use of *C. latifolia* in diabetic therapy.
Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Doktor Falsafah

KAJIAN AKTIVITI ANTIDIABETIK OLEH EKSTRAK \textit{Curculigo latifolia} KE ATAS KULTUR SEL DAN TIKUS

Oleh

NUR AKMAL BINTI ISHAK

Januari 2014

Pengerusi : Profesor Maznah Ismail, PhD
Fakulti : Institut Biosains


Pelbagai bahagian-bahagian pokok \textit{C. latifolia} (buah, akar dan daun) diekstrak menggunakan air suling dan kemudiannya disejukkeringkan menjadi serbuk. Jumlah kandungan fenolik dan aktiviti memerangkap radikal bebas oleh ekstrak buah, akar dan daun \textit{C. latifolia} telah ditentukan. Ekstrak buah dan akar \textit{C. latifolia} menunjukkan lebih tinggi aktiviti memerangkap radikal bebas (1.0 mg / ml) dan diikuti oleh ekstrak daun (1.2 mg / ml). Selain itu, ekstrak buah \textit{C. latifolia} juga mengandungi kandungan fenolik yang tinggi (95 mg GAE/100 g ekstrak) dan diikuti oleh akar (90 mg GAE/100 g ekstrak), ekstrak daun dalam air panas (100°C) (83 mg GAE/100 g ekstrak) dan ekstrak daun dalam air biasa (pada suhu bilik) (74 mg GAE/100 g ekstrak). Dalam kajian \textit{in vitro}, kepekatan ekstrak buah, akar dan daun \textit{C. latifolia} yang berbeza (0.01, 0.025, 0.05, 0.1, 0.5, 1.0 dan 3 mg/ml) telah disaring untuk mengesan sitotoksik ke atas sel pankreatik BRIN-BD11, L6 miotub dan 3T3 adiposit menggunakan asai 3-(4,5-dimetilthiazol-2-YL)-5-(3 -karboksimetoksifenil)-2-(4-sulfofenil)-2H-tetrazolium (MTS). Keputusan menunjukkan bahawa ekstrak buah dan akar \textit{C. latifolia} tidak menyebabkan toksik ke atas sel pankreatik BRIN-BD11, L6 miotub dan 3T3 adiposit. Walau bagaimana pun, ekstrak daun \textit{C. latifolia} pada kepekatan 2.3 mg/ml menyebabkan kematian sel BRIN-BD11 sebanyak 50%. Tambahan pula, kesan \textit{C. latifolia} sebagai agen antidiabetik telah dikaji dengan mengukur: (1) insulin yang dirembeskan oleh pankreatik BRIN-BD11, (2) pengangkutan radio label 2-Deoxy-D-glukosa (2DOG) oleh 3T3 adiposit dan L6.
miotub dan (3) adiponektin yang dirembeskan oleh 3T3 adiposit. Keputusan daripada asai insulin menunjukkan bahawa ekstrak akar C. latifolia meningkatkan 40% rembesan insulin lebih daripada rembesan basal diikuti oleh ekstrak buah C. latifolia (35%) dalam BRIN-BD11 pankreatik sel. Manakala, ekstrak daun tidak menunjukkan peningkatan yang ketara. Sementara itu, keputusan daripada aktiviti pengambilan 2DOG menunjukkan bahawa ekstrak buah C. latifolia meningkatkan dengan ketara (p<0.05) aktiviti 2DOG dengan kehadiran insulin sehingga 13 kali ganda (pada 0.05 mg/ml) dalam 3T3 adiposit dan 16 kali ganda (pada 0.1 mg/ml) dalam L6 miotub. Walaupun demikian, ekstrak akar C. latifolia pada 0.05 mg/ml meningkatkan dengan ketara (p<0.05) aktiviti 2DOG tanpa kehadiran insulin sehingga kepada 2 kali ganda dalam 3T3 adiposit dan L6 miotub. Kajian ini juga menunjukkan bahawa dengan kehadiran insulin, ekstrak daun C. latifolia pada 0.1 mg/ml meningkatkan 21 kali ganda rembesan adiponektin. Bagaimanapun tanpa kehadiran insulin, ekstrak akar C. latifolia meningkatkan 6 kali ganda rembesan adiponektin.

Keberkesanan ekstrak buah dan akar C. latifolia dalam meningkatkan rembesan insulin, pengangkutan 2DOG dan rembesan adiponektin di dalam kajian in vitro kemudiannya telah disahkan melalui kajian ke atas tikus yang diaruh diabetis. Kombinasi ekstrak buah dan akar (1:1) C. latifolia telah digunakan untuk merawat tikus yang diaruh diabetis melalui diet yang tinggi lemak (HFD) yang mengandungi kalori 56.9% disumbangkan oleh lemak dan suntikan STZ berdos rendah (40 mg/kg bw). Selepas tempoh penyesuaian, tikus telah diberi makan diet yang tinggi lemak selama 30 hari dan kemudiannya disuntik dengan 40 mg/kg b.w STZ melalui suntikan (iv) intravena pada ekor. Tikus telah dibahagikan kepada tujuh kumpulan; 1) tikus normal, 2) tikus obes (hanya diberi makan dengan HFD), 3) tikus diabetik (diaruh dengan HFD dan STZ berdos rendah), 4) tikus diabetik yang dirawat dengan 50 mg/kg b.w ekstrak buah:akar (1:1) C. latifolia, 5) tikus diabetik yang dirawat dengan 100 mg/kg b.w ekstrak buah:akar C. latifolia, 6) tikus diabetik yang dirawat dengan 200 mg/kg b.w ekstrak buah:akar C. latifolia dan 7) tikus diabetik yang dirawat dengan 10 mg/kg b.w glibenclamide. Tempoh rawatan adalah 30 hari. Sebelum dan selepas rawatan, parameter biokimia seperti plasma glukosa, insulin, adiponektin, jumlah kolesterol, lipoprotein berketumpatan tinggi (HDL), lipoprotein berketumpatan rendah (LDL), trigliserida (TG), urea, kreatinin, alanine aminotransferase (ALT) dan γ-glutamyltransferase (GGT) diukur. Keputusan menunjukkan bahawa 200 mg/kg b.w ekstrak buah:akar C. latifolia menurunkan dengan ketara (p<0.05) paras plasma glukosa sebanyak 65% dan 49% jumlah kolesterol. Di samping itu, dengan kepekatan yang sama ia juga meningkatkan paras plasma 12% insulin dan 41% adiponektin. Tambahan pula, 50, 100 dan 200 mg/kg b.w ekstrak buah:akar C. latifolia menunjukkan bahawa tahap urea, kreatinin, ALT dan GGT dalam tikus yang diaruh diabetik telah dikurangkan ke tahap sediakala selepas 30 hari rawatan.

Kesan pengawalaturan ekstrak buah:akar C. latifolia ke atas gen yang terlibat dalam metabolisme glukosa dan lipid telah dikaji pada tikus yang diaruh diabetis. Sepuluh gen; IGF-1, IRS-1, GLUT4, PPARY, PPARG, Adipor1, Adipor2, leptin, lipoprotein lipase dan lipase dianalisis menggunakan Sistem Analisis Genetik GenomeLab GeXP. Keputusan menunjukkan bahawa rawatan dengan 200 mg/kg b.w ekstrak buah:akar C. latifolia berkesan memperbaiki metabolisma glukosa secara berkesan ke atas tikus yang diaruh diabetik disebabkan oleh peningkatan ekspresi reseptor
isyarat insulin (IRS-1 (4 kali ganda) dan IGF-1 (4 kali ganda)), pengangkut glukosa (GLUT 4 (2 kali ganda)) dan reseptor peroksisom-proliferator (PPARγ (8 kali ganda) dan PPARα (2 kali ganda)). Ia juga menunjukkan peningkatan metabolisma lipid dengan meningkatkan reseptor adiponektin (AdipoR1 (5 kali ganda) dan AdipoR2 (4 kali ganda)), leptin (5 kali ganda), lipase (3 kali ganda) dan lipoprotein lipase (2 kali ganda).

Berdasarkan dapatan semasa, kesimpulannya bahawa ekstrak buah:akar C. latifolia menunjukkan sifat antidiabetik disebabkan oleh jumlah kandungan fenolik yang tinggi dan kebolehannya memerangkap radikal bebas. Ia berkesan meningkatkan metabolisme glukosa dan lipid dalam tikus yang diaruh diabetis melalui laluan AMPK dan PI3K dengan meningkatkan pengawalaturan gen IGF-1, IRS-1, GLUT4, PPARγ PPARα, AdipoR1, AdipoR2, leptin, lipoprotein lipase dan lipase. Semua keputusan menunjukkan potensi C. latifolia sebagai agen untuk terapi diabetik.
ACKNOWLEDGEMENTS

In the Name of Allah, the Most Gracious, the Most Merciful

First of all, I would like to thank to The Almighty Allah for giving me the strength to finish up this project without encountering any difficulty. I would like to extend my deepest appreciation and humble gratitude to my supervisor, Professor Dr. Maznah Ismail, for introducing me to study on C. latifolia potential as antidiabetic agent. Thank you also for your encouragement, inspiration and valuable advice in research culture.

Special thanks to my co-supervisors, Associate Professor Dr. Muhajir Hamid and Dr. Zalinah Ahmad for their attention, guidance, patience and wisdom during these years. Thank you also for your willingness in sharing your great in depth knowledge in diabetes and genetic research fields. I am grateful for the support.

Furthermore, I would like to thank to Mr. Ramli for assisting and helping me in handling rats while doing the animal study. I also would like to thank to Mrs. Siti Muskinah, Mr. Abidin, Mr. Chan Kim Wei, Miss Norsharina and Dr. Guru Raj. I am thankful for their help in handling machines, sharing their knowledge and experience, and also their valuable advice.

The daily lab work will not complete without good discussion partners, and I feel so lucky to have members like Nur Hazwani, Wan Abdul Aziz, Ghanya, Diana, Catherine, Aisyah, Effa, Zuraida, Asma, Nik Hasanah, Hajar, Ket Li, Syura, Nia, Foo Ji Biau, Nana, Syima, Ramlah and Yusri. Thank you for your valuable time, advice and knowledge. It is really a nice working atmosphere and most important thing is the friendship bond has been developed.

Extend deepest gratitude and devotion to my lovely family; babah, mama, angah and adik for your truly love, understanding and encouraging me to focus and work hard to finish up my study. Special thanks to babah, for the advice and you always encourage me to grab any opportunity and always looking forward. For my beloved husband, thank you for everything, your support, patient and understanding. You are always by my side throughout these years and I will remember all your kindness.

I also need to thank my little laptop for doing such a good job, not crashing and trashing some important files. Alhamdulillah.

Million thanks…
I certify that a Thesis Examination Committee has met on 27 January 2014 to conduct the final examination of Nur Akmal binti Ishak on her thesis entitled "Antidiabetic Activity of Curculigo latifolia Extracts in In Vitro and In Vivo Studies" in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the Doctor of Philosophy.

Members of the Thesis Examination Committee were as follows:

**Md Zuki bin Abu Bakar @ Zakaria, PhD**
Professor
Faculty of Veterinary Medicine
Universiti Putra Malaysia
(Chairman)

**Asmah binti Rahmat, PhD**
Professor
Faculty of Medicine and Health Science
Universiti Putra Malaysia
(Internal Examiner)

**Noorjahan Banu binti Mohammed Alitheen, PhD**
Associate Professor
Faculty of Biotechnology and Biomolecular Sciences
Universiti Putra Malaysia
(Internal Examiner)

**Abdalbasit Adam Mariod, PhD**
Professor
King Abdulaziz University
Saudi Arabia
(External Examiner)

NORITAH OMAR, PhD
Associate Professor and Deputy Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 17 February 2014
This thesis was submitted to the Senate of the Universiti Putra Malaysia and has been accepted as fulfillment of the requirement for the degree of Doctor of Philosophy. The members of the Supervisory Committee were as follows:

**Maznah Ismail, PhD**  
Professor  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Chairman)

**Muhajir Hamid, PhD**  
Associate Professor  
Faculty of Biotechnology and Biomolecular Sciences  
Universiti Putra Malaysia  
(Member)

**Zalina Ahmad, PhD**  
Lecturer  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Member)

---

**BUJANG BIN KIM HUAT, PhD**  
Professor and Dean  
School of Graduate Studies  
Universiti Putra Malaysia

Date:
DECLARATION

Declaration by graduate student

I hereby confirm that:
• this thesis is my original work;
• quotations, illustrations and citations have been duly referenced;
• this thesis has not been submitted previously or concurrently for any other degree at any other institutions;
• intellectual property from the thesis and copyright of thesis are fully-owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
• written permission must be obtained from supervisor and the office of Deputy Vice-Chancellor (Research and Innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
• there is no plagiarism or data falsification/fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software.

Signature: _______________________        Date: 27 January 2014

Name and Matric No.: Nur Akmal binti Ishak (GS17587)
Declaration by Members of Supervisory Committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) are adhered to.

Signature: __________________________
Name of Chairman of Supervisory Committee: Prof. Dr Maznah Ismail

Signature: __________________________
Name of Member of Supervisory Committee: Assoc. Prof Dr Muhajir Hamid

Signature: __________________________
Name of Member of Supervisory Committee: Dr Zalina Ahmad
# TABLE OF CONTENT

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABSTRACT</td>
<td>ii</td>
</tr>
<tr>
<td>ABSTRAK</td>
<td>v</td>
</tr>
<tr>
<td>ACKNOWLEDGEMENTS</td>
<td>viii</td>
</tr>
<tr>
<td>APPROVAL</td>
<td>ix</td>
</tr>
<tr>
<td>DECLARATION</td>
<td>xi</td>
</tr>
<tr>
<td>LIST OF TABLES</td>
<td>xviii</td>
</tr>
<tr>
<td>LIST OF FIGURES</td>
<td>xx</td>
</tr>
<tr>
<td>LIST OF ABBREVIATIONS</td>
<td>xxi</td>
</tr>
</tbody>
</table>

## CHAPTER

### 1 INTRODUCTION

1.1 Background of Study 1
1.2 Significant of Study 3
1.3 Objectives of the Study 4
  1.3.1 General Objectives 4
  1.3.2 Specific Objectives 4
1.4 Hypotheses of the study 5

### 2 LITERATURE REVIEW

2.1 The History of Diabetes Mellitus 6
  2.1.1 Definition and Classification of Diabetes Mellitus 7
  2.1.2 Pathogenesis of Type 2 Diabetes Mellitus 9
  2.1.3 Epidemiology of Type 2 Diabetes Mellitus Cases Worldwide and Malaysia 10

2.2 Treatment of type 2 Diabetes Mellitus 10
  2.2.1 Physical Activity 10
  2.2.2 Dietary Therapy 10
    2.2.2.1 Fat 11
    2.2.2.2 Carbohydrate and Fiber 11
    2.2.2.3 Protein 12
    2.2.2.4 Sweetener 12
  2.2.3 Pharmacotherapy 12

2.3 Role of Organs and Cytokines in Treating Type 2 Diabetes Mellitus 15
  2.3.1 Adipose Tissue and Its Adipokines 15
  2.3.2 Pancreas and Its Cytokines 16
  2.3.3 Insulin-like Growth Factor-1 (IGF-1) 17
2.4 Ethnopharmacology

2.4.1 Antidiabetic Activity of Medicinal Plants
2.4.2 Phenolic Compounds Exhibit Antioxidant Activity
2.4.3 Nutrigenomic of Diabetes
2.4.4 Nutrigenomic Mechanism of Active Compounds
2.4.5 Curculigo latifolia as a Diabetic Therapy

2.5 Animal Model of Diabetes: High-Fat Diet and Low Dose STZ Induced Diabetic Model

2.5.1 High Fat Diet
2.5.2 Mechanism of STZ
2.5.3 Combination of High-Fat Diet and Low Dose STZ

3 AQUEOUS EXTRACTS OF CURCULIGO LATIFOLIA EXHIBIT ANTIOXIDANT AND ANTIDIABETIC PROPERTIES IN IN VITRO

3.1 Introduction
3.2 Materials and Methods

3.2.1 Chemicals and Reagents
3.2.2 Preparation of C. latifolia Extract

3.2.2.1 Extraction of C. latifolia Fruits
3.2.2.2 Extraction of C. latifolia Leaves
3.2.2.3 Extraction of C. latifolia Root

3.2.3 Determination of Total Phenolic Compound (TPC) in C. latifolia
3.2.4 2, 2-Diphenyl-1-picrylhydrazyl (DPPH) Free Radical-Scavenging Activity in C. latifolia Extracts

3.2.5 In Vitro Study

3.2.5.1 Cell Culture
3.2.5.2 Cell Viability Assay
3.2.5.3 Insulin Secretion Assay
3.2.5.4 Deoxy-D-Glucose (2DOG) Uptake
3.2.5.5 Adiponectin Secretion Assay

3.2.6 Statistical Analysis
3.3 Results
3.3.1 Extraction Yield of *C. latifolia* Extracts
3.3.2 Total Phenolic Compounds in *C. latifolia*
3.3.3 Antioxidant Activity of *C. latifolia*
3.3.4 Cell Viability in the Presence of *C. latifolia*
3.3.5 Insulin Secreting Activity of *C. latifolia* Extract in BRIN BD11 Cell Line
3.3.6 Glucose Uptake Activity of *C. latifolia* Extract in 3T3-L1 Adipocyte and L6 Myotube Cell Lines
3.3.7 Adiponectin Secretion by Differentiated 3T3 Adipocyte Cell

3.4 Discussion

4 ANTIDIABETIC AND HYPOLIPIDEMIC ACTIVITIES OF *CURCULIGO LATIFOLIA* FRUIT:ROOT EXTRACT IN HIGH FAT DIET AND LOW DOSE STZ INDUCED DIABETIC RATS

4.1 Introduction
4.2 Materials and Methods
4.2.1 Preparation of *C. latifolia* Extract
4.2.2 Preparation of High Fat Diet (HFD)
4.2.3 Experimental Design
4.2.4 Animal Handling
4.2.5 Biological Assays
4.2.6 Plasma Glucose Level
4.2.7 Lipid Profile Analysis
4.2.7.1 Cholesterol
4.2.7.2 LDL-Cholesterol
4.2.7.3 HDL-Cholesterol
4.2.7.4 Triglycerides
4.2.8 Plasma Urea
4.2.9 Plasma Creatinine
4.2.10 Plasma ALT
4.2.11 Plasma GGT
4.2.12 Plasma Insulin
4.2.13 Plasma Adiponectin
4.2.14 Statistical Analyses

4.3 Results
4.3.1 Energy Contributed from HFD
5 MECHANISMS OF CURCULIGO LATIFOLIA IN ALLEVIATING INSULIN RESISTANCE THROUGH ALTERING EXPRESSION OF GENES INVOLVED IN GLUCOSE AND LIPID METABOLISMS

5.1 Introduction 77
5.2 Materials and Methods 79
  5.2.1 Preparation of C. latifolia Extract 79
  5.2.2 Experimental Design 79
  5.2.3 Isolation of Total RNA 79
  5.2.4 RNA Purification 80
  5.2.5 Determination of RNA Total Yield and Purity 80
  5.2.6 Designing Primer 80
  5.2.7 Optimization of GeXP Variables for Detection of Differently Expressed Gene between Group Treatments
    5.2.7.1 Primer, Sample and KAN’ Concentrations 82
  5.2.8 cDNA Synthesis and PCR Amplification 82
  5.2.9 Quantification of Differently Expressed Gene between Group Treatments using GenomeLab GeXP Genetic Analysis System 83
  5.2.10 Statistical Analysis 84

5.3 Results 84
  5.3.1 Total RNA Yield and Purity 84
  5.3.2 GeXP Optimization 84
  5.3.3 Expression of Candidate Genes Using GeXP Analyzer 85

5.4 Discussion 89
6 GENERAL DISCUSSION, CONCLUSION AND RECOMMENDATION FOR FUTURE RESEARCH

6.1 General Discussion 92
6.2 Conclusion 93
6.3 Recommendation for Future Research 94

REFERENCES 95
APPENDICES 123
BIODATA OF STUDENT 134
LIST OF PUBLICATIONS 137
# LIST OF TABLES

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>Classification and mechanism of action of antidiabetic drug</td>
<td>12</td>
</tr>
<tr>
<td>2.2</td>
<td>Local market demand, local production, export and imports (International Trade Centre, 2005)</td>
<td>29</td>
</tr>
<tr>
<td>2.3</td>
<td>Candidate genes of type 2 diabetes mellitus</td>
<td>24</td>
</tr>
<tr>
<td>2.4</td>
<td>Animal models of diabetes</td>
<td>28</td>
</tr>
<tr>
<td>3.1</td>
<td>Yield of <em>C. latifolia</em> extracts</td>
<td>38</td>
</tr>
<tr>
<td>3.2</td>
<td>Total phenolic compounds of <em>C. latifolia</em></td>
<td>38</td>
</tr>
<tr>
<td>3.3</td>
<td>Antioxidant activity of <em>C. latifolia</em></td>
<td>39</td>
</tr>
<tr>
<td>3.4</td>
<td>Linear correlation coefficient (r) between antioxidant activity and total phenolic content (TPC) of <em>C. latifolia</em> extracts.</td>
<td>39</td>
</tr>
<tr>
<td>3.5</td>
<td>The effect of <em>C. latifolia</em> extract on BRIN-BD11 cells in insulin secretion after 1h of treatment</td>
<td>43</td>
</tr>
<tr>
<td>3.6</td>
<td>Effect of <em>C. latifolia</em> extracts on 2 DOG uptake activity in the presence or absence of insulin in differentiated 3T3 adipocytes</td>
<td>45</td>
</tr>
<tr>
<td>3.7</td>
<td>Effect of <em>C. latifolia</em> extract on 2 DOG uptake activity in the presence or absence of insulin in L6 myotubes</td>
<td>46</td>
</tr>
<tr>
<td>3.8</td>
<td>Effect of <em>C. latifolia</em> extract on adiponectin secretion with presence and absence of insulin in differentiated 3T3 adipocytes</td>
<td>48</td>
</tr>
<tr>
<td>4.1</td>
<td>Nutrient composition of NPD and HFD</td>
<td>54</td>
</tr>
<tr>
<td>4.2</td>
<td>Energy contributed from NPD and HFD</td>
<td>63</td>
</tr>
<tr>
<td>4.3</td>
<td>The mean of body weight and the body weight gain during Phase I</td>
<td>64</td>
</tr>
<tr>
<td>4.4</td>
<td>The mean of body weight and the body weight gain during Phase II</td>
<td>64</td>
</tr>
<tr>
<td>Section</td>
<td>Title</td>
<td>Page</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>4.5</td>
<td>The plasma glucose level and percentage of plasma glucose changes during Phase I</td>
<td>65</td>
</tr>
<tr>
<td>4.6</td>
<td>The plasma glucose level and percentage of plasma glucose changes during Phase II</td>
<td>66</td>
</tr>
<tr>
<td>4.7</td>
<td>Hypolipidemic effect of <em>C. latifolia</em> extract on HFD and low dose STZ induced diabetic rats</td>
<td>68</td>
</tr>
<tr>
<td>4.8</td>
<td>Effect of <em>C. latifolia</em> extracts on ALT, GGT, urea and creatinine levels on HFD and low dose STZ induced diabetic rats</td>
<td>72</td>
</tr>
<tr>
<td>5.1</td>
<td>List of Genes</td>
<td>81</td>
</tr>
<tr>
<td>5.2</td>
<td>Master mix for optimization of primer, sample and KAN' concentrations</td>
<td>82</td>
</tr>
<tr>
<td>5.3</td>
<td>cDNA synthesis</td>
<td>83</td>
</tr>
<tr>
<td>5.4</td>
<td>PCR reaction mix</td>
<td>83</td>
</tr>
<tr>
<td>5.5</td>
<td>Thermal cycling program for PCR</td>
<td>83</td>
</tr>
<tr>
<td>5.6</td>
<td>Final Master mix</td>
<td>85</td>
</tr>
<tr>
<td>5.7</td>
<td>Expression of Candidate Genes in Muscle Tissue</td>
<td>86</td>
</tr>
<tr>
<td>5.8</td>
<td>Expression of Candidate Genes in Adipose Tissue</td>
<td>88</td>
</tr>
</tbody>
</table>
### LIST OF FIGURES

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>Schematic depiction of the insulin regulated intracellular signal transduction cascade (Frojdo et al., 2009)</td>
<td>16</td>
</tr>
<tr>
<td>2.2</td>
<td>Putative mechanisms by which IGFBP-1 and IGFBP-2 modulate insulin sensitivity independent of IGF-I (Wheatcroft and Kearney, 2009)</td>
<td>17</td>
</tr>
<tr>
<td>2.3</td>
<td>Dietary factors and the regulation of DNA methylation (Trujillo et al., 2006)</td>
<td>23</td>
</tr>
<tr>
<td>2.4</td>
<td>Bioactive food components can influence genetic and epigenetic events associated with a host of disease processes (Trujillo et al., 2006)</td>
<td>26</td>
</tr>
<tr>
<td>2.5</td>
<td>Picture of <em>Curculigo latifolia</em> plant</td>
<td>27</td>
</tr>
<tr>
<td>3.1</td>
<td>The effect of <em>C. latifolia</em> extract on differentiated L6 myoblast cell viability after 72 h of exposure measured using the MTS assay</td>
<td>40</td>
</tr>
<tr>
<td>3.2</td>
<td>The effect of <em>C. latifolia</em> extract on differentiated 3T3 adipocyte cell viability after 72 h of exposure measured using the MTS assay</td>
<td>41</td>
</tr>
<tr>
<td>3.3</td>
<td>The effect of <em>C. latifolia</em> extract on BRIN BD11 cell viability after 72 h of exposure measured using the MTS assay</td>
<td>42</td>
</tr>
<tr>
<td>4.1</td>
<td>Experimental design of in vivo study</td>
<td>56</td>
</tr>
<tr>
<td>4.2</td>
<td>Energy contributed from NDP and HFD</td>
<td>64</td>
</tr>
<tr>
<td>4.3</td>
<td>Effect of <em>C. latifolia</em> fruit:root extract on fasting plasma insulin at before (week 0) and after treatment (week 4)</td>
<td>69</td>
</tr>
<tr>
<td>4.4</td>
<td>Effect of <em>C. latifolia</em> fruit:root extract on fasting plasma adiponectin at before (week 0) and after treatment (week 4).</td>
<td>70</td>
</tr>
</tbody>
</table>
LIST OF ABBREVIATIONS

AdipoR1  Adiponectin receptor 1
AdipoR2  Adiponectin receptor 2
AGE  Advanced glycation end-product
ALT  Alanine aminotransferase
AMPK  AMP-activated protein kinase
ATP  Adenosine triphosphate
CO₂  Carbon dioxide
CVD  Cardiovascular disease
DEPC  Diethyl pyrocarbonate
DM  Diabetes mellitus
DNA  Deoxyribonucleic acid
ELISA  Enzyme-linked immunosorbent assay
ER  Endoplasmic reticulum
FFA  Free fatty acid
FRIM  Forest Research Institute Malaysia
G-6-Pase  Glucose-6-phosphatase
GGT  Gamma glutamyltransferase
GI  Glycaemic index
GLP-1  Glucagon-like peptide-1
GLUT  Glucose transporter
HbA1c  Glycated hemoglobin
HDL  High density lipoprotein
HFD  High fat diet
HOMA  Homeostasis model assessment-estimated
ICA  Islet cell antibody
ID  Idiopathic
IDDM  Insulin dependent diabetes mellitus
IDF  International Diabetes Federation
IFG  Impaired fasting glucose
IGF-1  Insulin-like growth factor-1
IGT  Impaired glucose tolerance
IL-6  Interleukin-6
IRS  Insulin receptor substrate
LDL  Low density lipoprotein
MARDI  Malaysian Agricultural Research and Development Institute
MODY  Maturity onset diabetes of the young
MUFA  Monosaturated fatty acids
NIDDM  Non-insulin dependent diabetes mellitus
NPCB  National Pharmaceutical Control Bureau
NPD  Normal pallet diet
PCR  Polymerase chain reaction
PEPCK  Phosphoenolpyruvate
<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPAR</td>
<td>Peroxisome proliferator-activated receptor</td>
</tr>
<tr>
<td>PUFA</td>
<td>Polyunsaturated fatty acids</td>
</tr>
<tr>
<td>RNA</td>
<td>Ribonucleic acid</td>
</tr>
<tr>
<td>SAFA</td>
<td>Saturated fatty acids</td>
</tr>
<tr>
<td>SD</td>
<td>Sprague-Dawley</td>
</tr>
<tr>
<td>STZ</td>
<td>Streptozotocin</td>
</tr>
<tr>
<td>TG</td>
<td>Triglycerides</td>
</tr>
<tr>
<td>TNF-α</td>
<td>Tumor necrosis factor-α</td>
</tr>
<tr>
<td>TZD</td>
<td>Thiazolidinediones</td>
</tr>
<tr>
<td>UPM</td>
<td>Universiti Putra Malaysia</td>
</tr>
<tr>
<td>VLDL</td>
<td>Very low density lipoprotein</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>carboxykinase</td>
<td></td>
</tr>
</tbody>
</table>

CHAPTER 1

INTRODUCTION

1.1 Background of Study

Diabetes mellitus (DM) is a metabolic disorder which has become one of the major worldwide health issues. World Health Organization (WHO) (2006) has classified DM into two major types which are type 1 and type 2 according to clinical stages and aetiological types. Type 1 DM referred to β-cell destruction in which insulin is required and it also known as insulin-dependent diabetes mellitus (Tuomi, 2005). Meanwhile, Monnier et al., (2008) specifically defined type 2 DM as β-cell dysfunction, insulin resistance and excess of glucose production from liver. Insulin resistance is referred to impaired insulin-mediated glucose clearance into peripheral tissues. As this disease progresses, it will damage other tissues and can lead towards several complications such as cardiovascular diseases, nephropathy, retinopathy and neuropathy (Steinberger and Daniels, 2003).

The incidence of Type 2 DM has become a worldwide epidemic and according to the International Diabetes Federation (IDF) (2012) report, there are approximately 366 million people who are suffering from this disease. It is projected that the global prevalence could reach 567 million by 2030 if no urgent action is taken. The highest rate of diabetes are found in India with a current figure of 40.9 million and followed by China with 39.8 million. Furthermore, Pakistan, Japan, USA, Russia and Germany are also widely affected by diabetes (IDF, 2012). Data from National Diabetes Statistics (2011) indicate that the total prevalence of diabetes in the United State is 25.8 million where 18.8 million people have been diagnosed and another 7 million people are undiagnosed. Meanwhile, people with prediabetes are approximately 79 million. The statistics also indicate that 215,000 adolescents under 20 years are diagnosed to be diabetic. Furthermore, diabetes prevalence affects 10.9 million adults aged 65 years and above in the US (National Diabetes Statistics, 2011).

Diabetes prevalence in Malaysia has been showing an upward trend. As at 2006, there were 1.5 million people aged 18 years and above who were diagnosed with type 2 DM (National Diabetes Institution, 2006). According to the third National Health and Mobility Survey (NHMS III) in 2006, diabetes prevalence among rural and urban areas significant increased from 10.5% to 12.1%. Meanwhile, diabetes prevalence among patients 18 years and above was 11.6%, while it was 14.9% in patients 30 years and above. The survey also indicated that Indians had the highest diabetes prevalence (19.9%) followed by Malays (11.9%) then Chinese (11.4%). However, there were no differences based on gender or income status (Zanariah et al., 2006). This survey indicated that diabetes was growing in Malaysia and interventions were needed to curb the rising trend.

Lifestyle, dietary composition and genes are determined to be major factors that affect both diabetes development and complications (Kontogianni et al., 2012; Weber and Narayan, 2008; Chan et al., 2007). Shift from traditional lifestyle to
urban lifestyle has changed mankind activity. According to Leahy (2005), watching television too much, less physical activity, wide availability of cars and abundance of high calorie foods are the current problem in modern living. High calorie foods such as fat have greatly affect the development of diabetes where it influences glucose metabolism by defective cell membrane function, insulin signaling, enzyme activity and gene expression (Risérus et al., 2009). Studies based on interaction between nutrient and genetic is known as nutrigenomic. Furthermore, interaction between nutrient and genetic makeup can affect physiological changes in human where nutrient influences the genes during transcription process (Trujillo et al., 2006). In T2DM, influence of nutrient and environmental factors in genetic predisposition involves multiple genes (Kaput et al., 2007). Some genes are involved in insulin signaling pathway such as glucose transporter 4 (GLUT4), insulin (INS) and insulin receptor (INSR), glucose homeostasis pathway such as glucose transporter 2 and 4 (GLUT 2 and GLUT4), glucose-6-phosphatase (G6PC) and lipoprotein metabolism such as peroxisome proliferator-DFWLYDWHGUHFHSWRRUVDQG/3385.3385DQG3385/3KLOOLSVHWDODQG

Understanding the pathogenesis of T2DM has provided information to the scientists to find a better approach in preventing and treating diabetic problem. Changing bad lifestyle habit into mild exercise is a pre-treatment for the diabetic patient. Through exercise, excess weight can be reduced by increasing the energy expenditure. Thus, insulin sensitivity and glucose tolerance will improve (Hu and Manson, 2003). Meanwhile, taking quality diet which composes of low fat, high fiber and several micronutrients are recommended in order to prevent and treat T2DM (Franz et al., 2003). Apart from that, several alternative sweeteners such as aspartame, saccharin, cyclamate and acesulfame-K are another approach that can be used to treat diabetes. These alternative sweeteners are substitutes from natural and some are artificial. Besides, it has less-calorie and non-nutritive value (Bastaki, 2005). Hence, it could reduce energy intake among diabetic patient. Apart from that, alternative sweeteners also have high intensity of sweet taste property and due to this property it becomes preferable choice among diabetic patients. They only need to take a small amount of it to make their meal taste sweet.

In addition to exercise and dietary management, pharmaceutical approach can also be used to treat type 2 DM. At present time, therapeutic drug has been used to treat diabetes through multiple target sides. To date, there are five major classes of therapeutic drug and it had been classified according to their mechanism of action; VXOIRQOXUHDV ELIXDQLGHV WKLDJROLGLQHGLRQHV -PHOLWQLGH DQG inhibitor. Each of these drugs has their own mode of actions to treat diabetes either through reduction of glucose absorption in intestinal, improve insulin secretion or triggering PPAR (Patel et al., 2012). However, according to Bastaki (2005), combination of two drugs such as metformin and sulfonylurea can increase the hypoglycemic activity where it treats diabetes through two modes of action. Despite of antidiabetic drugs effectiveness, prolong usage of it will cause adverse effect.

Besides using alternative sweeteners and antidiabetic drugs, natural products are also used in treating diabetes. There are several plants that posses medicinal properties and approximately 800 plants have been identified with antidiabetic properties (Warjeet Singh, 2011). Studies have reported that these plants have the ability to reduce blood glucose and improve insulin secretion (Dheer and Bhatnagar, 2010).
Meanwhile, according to Malviya et al. (2010), secondary metabolites from plant such as phenolic, alkaloids and glycosides are the one which implicate as having antidiabetic effect. Among those secondary metabolites, phenolic compounds are the one which abundantly present in plants and demonstrated having antioxidant, antidiabetic and antiobesity properties (Randhir and Shetty, 2007).

Malaysia is rich with natural resources and known to be world’s 17 mega biodiversity-rich countries (Ang, 2004; Institute for Medical Research, 2002). There are about 1300 plants that have been used as traditional medicine (Jantan, 2004). Every part of the plant has been used and obtains active component which exhibit therapeutic effect. Curculigo latifolia plant is belonging to Hypoxidaceae family. It is a shrub tree and it can be found in the west Malaysia (Mohd Firdaus et al., 2010). C. latifolia is also called Lemba or Lumbah among local community in Malaysia. Traditionally, it has been used as sweetener in drinks (Chooi, 2006). This shrub tree consists of berry-like fruit and this fruit exhibits both sweet tasting and taste modifying activities (Kant, 2005). Curculin and neoculin have been identified as proteins that possess those activities (Ibuka et al., 2006). Despite C. latifolia is sweet and can be use as alternative sweetener for diabetic patient, there is no scientific study on C. latifolia as antidiabetic agent.

1.2 Significant of Study

There are many adverse side effects of using artificial and synthetic sweetener. It causes several complications such as brain tumors, hallucinations, seizures and bladder cancer (Renwick, 2006; Academy of Nutrition and Dietetics, 2012). The controversy about the side effect of therapeutic drugs and alternative sweetener has already drawn the attention of researchers to look for natural nutraceutical and nature sweeteners which are more effective and less toxic (Okokon et al., 2012; Jia et al., 2009). The sweet taste of C. latifolia fruit has been applied and used as sweetener in chewing gum, drinks and meals (Kurihara and Nirasawa, 1994). However, the use of C. latifolia as sweetener for diabetic patient is not well studied. It can be expected as a new replacement for table sugar and synthetic sweeteners.

Apart from adverse side effects of synthetic sweetener, prolong consumption of GLDEHWLFGUXJVF RXOGDVRFIIHFWSDWLHQWV'KHDOWK$FRUGLQJWR0F/DX colleagues (2001), sulfonylureas cause hypoglycemia, increase in body weight, gastrointestinal (GI) disturbance and headache to the user. Besides, metformin has been reported to cause abdominal pain, diarrhea, nausea and lactic acidosis to the diabetic patient (Nzerue et al., 2003). Other diabetic drug that cause adverse side effect is thiazolidinediones where it causes hepatotoxicity after prolong usage (Amori et al., 2007). Apart from adverse side effect, antidiabetic drug also has limited mode of action. Available diabetic drugs only show single mode of action in treating diabetes and it needs to combine with another class of antidiabetic drug to make these drugs more efficient such as combination of metformin and sulfonylurea (Bastaki, 2005).

Despite of using synthetic sweeteners and drugs, natural souces have become alternative choices for diabetic patients. This is because it is affordable and less toxic (Singh et al., 2007). Several plants have been identified and showed antidiabetic
properties. However, there is no study has been done on *C. latifolia* extracts towards type 2 diabetes. Therefore, this study was conducted to determine the effect of *C. latifolia* extracts in *in vitro* and *in vivo*. In *in vitro* study, total phenol compounds and antioxidant properties of *C. latifolia* fruit, root and leaf extracts were determined. Then, these extracts were tested on cell lines (BRIN-BD11 pancreatic, 3T3 adipocytes and L6 myotubes) to determine mode of *C. latifolia* antidiabetic action either through cytokine (insulin and adiponectin) secretions or glucose uptake. Meanwhile in *in vivo* study, combination of *C. latifolia* fruit and root extracts were used to assess antidiabetic effect on diabetic-induced rats. Furthermore, the interaction of *C. latifolia* fruit:root extracts on regulatory genes in glucose and lipid metabolisms were also determined.

The rising number of diabetic patients have urged researches to find more effective diabetic treatment. Treating diabetic problems at early stage without cause complication at prolong usage is preferable. A major target in current study is to identify novel strategies to overcome diabetic problems based on natural sources which contain antidiabetic properties. Besides, finding from this study also give some opportunities to develop new nutraceutical and pharmaceutical products from indigenous plants. This is the reason why this study should be carried out successfully.

1.3 Objectives of the Study

1.3.1 General Objective

The main objective of this study was to investigate the antidiabetic properties of *C. latifolia* extract on diabetes *in vitro* and *in vivo*.

1.3.2 Specific Objectives

1. To determine total phenolic contents and free radical scavenging activity of *C. latifolia* extracts.

2. To determine antidiabetic properties of *C. latifolia* extracts through insulin secretion in BRIN BD11 cells and adiponectin secretion in 3T3 adipocytes.

3. To determine antidiabetic properties of *C. latifolia* extracts through glucose uptake activity in 3T3 adipocyte and L6 myotubes.

4. To investigate the antidiabetic and hypolipidemic properties of *C. latifolia* fruit:root extracts in a diabetic model (*in vivo*).

5. To determine the interaction between *C. latifolia* fruit:root extracts with insulin signaling genes in diabetic model.
1.4 Hypotheses of the Study

1. The *C. latifolia* fruit and root extracts exhibit high total phenolic content and scavenging activity.
2. The *C. latifolia* fruit and root extracts exhibit antidiabetic properties by increase insulin secretion in BRIN BD11 and adiponectin secretion in 3T3 adipocyte.
3. The *C. latifolia* fruit and root extracts exhibit antidiabetic properties by increase glucose uptake activity in 3T3 adipocyte and L6 myotubes.
4. The *C. latifolia* fruit:root (1:1) extract possess antidiabetic and hypolipidemic properties by treating diabetic problem in diabetic model.
5. The *C. latifolia* fruit:root (1:1) extract trigger up regulation of insulin signaling genes in diabetic model.
REFERENCES


Cheel, J., Theoduloz, C., Rodríguez, J. A., Peter, D.S. and Caligari, G. (2007). Free radical scavenging activity and phenolic content in achenes and thalamus from...
Fragaria chiloensis ssp. chiloensis, F. vesca and F. x ananassa cv. Chandler.
Food Chemistry. 102(1):36-44.


